- 1.
FDA. Accelerated Approval Program. https://www.fda.gov/drugs/information-health-care-professionals-drugs/accelerated-approval-program Lest 11.8.2021.
- 2.
Mullard A. Controversial Alzheimer's drug approval could affect other diseases. Nature 2021; 595: 162–3. [PubMed][CrossRef]
- 3.
Biogen. European Medicines Agency Accepts Biogen's Aducanumab Marketing Authorization Application for Alzheimer's Disease. https://investors.biogen.com/news-releases/news-release-details/european-medicines-agency-accepts-biogens-aducanumab-marketing Lest 13.8.2021.
- 4.
Kashoki M, Hanaizi Z, Yordanova S et al. A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: Concordance, discordance, and why. Clin Pharmacol Ther 2020; 107: 195–202. [PubMed][CrossRef]
- 5.
Holmes C, Boche D, Wilkinson D et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216–23. [PubMed][CrossRef]
- 6.
Richard E, den Brok MGHE, van Gool WA. Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease. Alzheimers Dement 2021; 17: 1051–5. [PubMed][CrossRef]
- 7.
Alzforum. Aducanumab Approved to Treat Alzheimer's Disease. https://www.alzforum.org/news/research-news/aducanumab-approved-treat-alzheimers-disease Lest 28.7.2021.
- 8.
Alzforum. Aducanumab Approval Sparks Backlash. https://www.alzforum.org/news/research-news/aducanumab-approval-sparks-backlash Lest 19.8.2021.
- 9.
CNBC. Biogen CEO on FDA approval for its Alzheimer's drug. https://www.cnbc.com/video/2021/06/07/biogen-ceo-on-fda-approval-for-its-alzheimers-drug.html Lest 28.7.2021.
- 10.
Biogen. Biogen and Eisai launch multiple initiatives to help patients with Alzheimer's disease access ADUHELM™. http://media.biogen.com/news-releases/news-release-details/biogen-and-eisai-launch-multiple-initiatives-help-patients Lest 28.7.2021.
- 11.
Norges Bank. Valutakurser. https://www.norges-bank.no/tema/Statistikk/Valutakurser/ Lest 11.8.2021.
- 12.
OECD. Health at a Glance 2019: OECD Indicators. https://read.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2019_7f66369c-en#page2 Lest 13.8.2021.
- 13.
Statistisk sentralbyrå. Helseregnskap. https://www.ssb.no/nasjonalregnskap-og-konjunkturer/nasjonalregnskap/statistikk/helseregnskap Lest 11.8.2021.
- 14.
Pahnke J, Langer O, Krohn M. Alzheimer's and ABC transporters–new opportunities for diagnostics and treatment. Neurobiol Dis 2014; 72: 54–60. [PubMed][CrossRef]
- 15.
Perloff MD, von Moltke LL, Störmer E et al. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601–8. [PubMed][CrossRef]
- 16.
Hofrichter J, Krohn M, Schumacher T et al. Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr Alzheimer Res 2013; 10: 1057–69. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.